Asthma treatment with inhaled corticosteroids versus antileukotrienes: What exhaled nitric oxide studies do and do not tell us

Annals of Allergy, Asthma and Immunology

Volumn 87, Issue 4, 2001, Pages 257-260

  Dykewicz, M S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE; PRANLUKAST; ZAFIRLUKAST;

ALLERGIC ASTHMA; BRONCHUS HYPERREACTIVITY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; IMMUNOREGULATION; LUNG FUNCTION; LYMPHOCYTE PROLIFERATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034768536     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62237-5     Document Type: Editorial

References (51)

1. Increased amount of nitric oxide in exhaled air of asthmatics
2. Effect of inhaled Larginine on exhaled nitric oxide in normal and asthmatic subjects
3. The effect of low dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatics and comparison with oral zafirlukast
4. Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic?
5. New insights into the regulation of inducible nitric oxide synthesis
6. Induction of nitric oxide synthase in asthma
7. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects
8. Allergen-induced late asthmatic reactions are associated with elevated of exhaled nitric oxide
9. Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children
10. Nitric oxide exhalation by mice with congenital deficiency of nitric oxide synthase isoforms
11. Endogenous nitric oxide in allergic airway disease
12. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells
13. Inhalation of nitric oxide modulates adult human bronchial tone
14. Endogenous nitric oxide inhibits leukotriene B4 release from rat alveolar macrophages
15. Endogenous nitric oxide inhibits the synthesis of cycloxygenase products and interleukin-6 by rat Kupffer cells
16. Nitric oxide regulation of asthmatic airway inflammation with segmental allergen challenge
17. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle
18. Exhaled nitric oxide: Relationship to clinicophysiological markers of asthma severity
19. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids
20. Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma
21. Atopy influences exhaled nitric oxide levels in adult asthmatics
22. Exhaled nitric oxide levels correlate with measures of disease control in asthma
23. Changes in sputum eosinophils predict loss of asthma control
24. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment: The AMPUL Study Group
25. Corticosteroids decrease exhaled nitric oxide in children with acute asthma
26. Expired nitric oxide levels during treatment of acute asthma
27. Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticoids in children
28. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma
29. An inhaled steroid improves markers of airway inflammation in patients with mild asthma
30. Exhaled nitric oxide, serum ECP and airway responsiveness in mild asthmatic children
31. Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma
32. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma
33. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast
34. Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics
35. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study
36. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
37. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma
38. Atopy influences exhaled nitric oxide levels in adult asthmatics
39. Exhaled nitric oxide in patients with asthma: Association with NOS1 genotype
40. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults
41. Leukotriene receptor antagonists in the treatment of asthma: Implications for eosinophilic inflammation
42. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
43. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial
44. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals
45. Airway remodeling and repair
46. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
47. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
48. Inflammatory markers in clinical practice
49. Algorithm for the diagnosis and management of asthma: A practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology
50. Global initiative for asthma (GINA) and its objectives